Australia markets open in 9 hours 43 minutes

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.5100-0.0400 (-2.58%)
At close: 04:00PM EDT
1.4900 -0.02 (-1.32%)
After hours: 07:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5500
Open1.5500
Bid1.5000 x 3100
Ask1.5300 x 1800
Day's range1.4820 - 1.5800
52-week range0.3500 - 5.2000
Volume648,610
Avg. volume6,041,030
Market cap47.53M
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)-2.5480
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date20 Aug 2015
1y target est15.50
  • GlobeNewswire

    Catalyst Biosciences Sells Complement Portfolio for $60 Million

    SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f

  • GlobeNewswire

    Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

    SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader protease, for the potential treatment of dry age-related macular degeneration (“AMD”) and now have full rights to two wholly-owned, potential best-in-class complement candidates that may provide compelling opportunities in o

  • Simply Wall St.

    Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely

    We can readily understand why investors are attracted to unprofitable companies. For example, although...